Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efzofitimod - aTyr Pharma

Next Previous
Drug Profile

Efzofitimod - aTyr Pharma

Alternative Names: ATY 1923; ATYR-1923; iMod.Fc; KRP-R120; Stalaris

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator aTyr Pharma
  • Developer aTyr Pharma; Foundation for Sarcoidosis Research; Kyorin Pharmaceutical
  • Class Anti-inflammatories; Antifibrotics; Antirheumatics; Antivirals; Immunoglobulin Fc fragments; Proteins; Recombinant fusion proteins
  • Mechanism of Action Neuropilin-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pulmonary sarcoidosis
  • Phase II COVID-19 pneumonia; Interstitial lung diseases
  • Preclinical Rheumatoid arthritis
  • No development reported Pulmonary fibrosis

Most Recent Events

  • 04 Jun 2025 Interim adverse events, efficacy and pharmacodynamics data from a phase II trial in Interstitial lung diseases released by aTyr Pharma
  • 13 Mar 2025 aTyr Pharma holds a Type C meeting with the US FDA to discuss the statistical analysis plan (SAP) for the phase III EFZO-FIT™ study
  • 02 Oct 2024 Efzofitimod - aTyr Pharma receives Orphan Drug status for Sarcoidosis in Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top